PL2951202T3 - Cząsteczki wiążące rozpoznające mage a1 o wysokiej awidności - Google Patents
Cząsteczki wiążące rozpoznające mage a1 o wysokiej awidnościInfo
- Publication number
- PL2951202T3 PL2951202T3 PL14702238T PL14702238T PL2951202T3 PL 2951202 T3 PL2951202 T3 PL 2951202T3 PL 14702238 T PL14702238 T PL 14702238T PL 14702238 T PL14702238 T PL 14702238T PL 2951202 T3 PL2951202 T3 PL 2951202T3
- Authority
- PL
- Poland
- Prior art keywords
- binding molecules
- high avidity
- avidity binding
- molecules recognizing
- mage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13153081 | 2013-01-29 | ||
| PCT/EP2014/051726 WO2014118236A2 (en) | 2013-01-29 | 2014-01-29 | High avidity antigen recognizing constructs |
| EP14702238.8A EP2951202B1 (en) | 2013-01-29 | 2014-01-29 | High avidity binding molecules recognizing mage-a1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2951202T3 true PL2951202T3 (pl) | 2020-09-21 |
Family
ID=47623953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14702238T PL2951202T3 (pl) | 2013-01-29 | 2014-01-29 | Cząsteczki wiążące rozpoznające mage a1 o wysokiej awidności |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10377808B2 (OSRAM) |
| EP (2) | EP3747899A3 (OSRAM) |
| JP (1) | JP6639233B2 (OSRAM) |
| CN (1) | CN105377886B (OSRAM) |
| AU (2) | AU2014211454B2 (OSRAM) |
| CA (1) | CA2899679C (OSRAM) |
| DK (1) | DK2951202T3 (OSRAM) |
| ES (1) | ES2804538T3 (OSRAM) |
| HU (1) | HUE050390T2 (OSRAM) |
| PL (1) | PL2951202T3 (OSRAM) |
| PT (1) | PT2951202T (OSRAM) |
| SI (1) | SI2951202T1 (OSRAM) |
| WO (1) | WO2014118236A2 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012104843A1 (en) | 2011-02-06 | 2012-08-09 | Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science | Affinity maturated t cell receptors and use thereof |
| JP6712261B2 (ja) * | 2014-08-04 | 2020-06-24 | フレッド ハッチンソン キャンサー リサーチ センター | Ｗｔ−１に特異的なｔ細胞免疫治療 |
| GB201417803D0 (en) | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| US12364757B2 (en) * | 2015-10-01 | 2025-07-22 | Ospedale San Raffaele S.R.L | TCR and uses thereof |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520544D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| DK3440105T3 (da) * | 2016-04-08 | 2022-06-13 | Immunocore Ltd | T-cellereceptorer |
| CN106084042B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗MAGEA1的全分子IgG抗体及其应用 |
| EP3515935A4 (en) * | 2016-09-23 | 2019-09-04 | Lion TCR Pte. Ltd. | HBV-Antigen specific binding molecules and fragments thereof |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| MY192819A (en) * | 2016-12-08 | 2022-09-12 | Immatics Biotechnologies Gmbh | Novel t cell receptors and immune therapy using the same |
| CN108250289B (zh) * | 2016-12-28 | 2021-10-08 | 香雪生命科学技术（广东）有限公司 | 源自于mage b6的肿瘤抗原短肽 |
| BR112019018863A8 (pt) * | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
| CN108929378B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别prame抗原的t细胞受体及编码该受体的核酸 |
| WO2019046818A1 (en) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER |
| GB2596461B (en) * | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| TWI850360B (zh) | 2019-04-04 | 2024-08-01 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途 |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| EP3997116A1 (en) * | 2019-07-09 | 2022-05-18 | Medigene Immunotherapies GmbH | Magea10 specific t cell receptors and their use |
| GB201915282D0 (en) * | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| CN113684258B (zh) * | 2020-05-18 | 2024-08-20 | 上海赛比曼生物科技有限公司 | 用于检测鼠源tcr转基因拷贝数的试剂盒及方法 |
| JP7781085B2 (ja) * | 2020-06-25 | 2025-12-05 | ザ・メソジスト・ホスピタル | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 |
| IL276599A (en) * | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN112279908B (zh) * | 2020-10-23 | 2024-03-19 | 魏放 | 识别ebv抗原短肽的t细胞受体及其应用 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2023083864A1 (en) | 2021-11-09 | 2023-05-19 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN114539386B (zh) * | 2022-04-27 | 2022-07-26 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| CN120476137A (zh) | 2022-08-18 | 2025-08-12 | 英美偌科有限公司 | 对mage a4具有特异性的t细胞受体融合蛋白 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025027087A1 (en) | 2023-07-31 | 2025-02-06 | T-Knife Gmbh | A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease |
| WO2025027088A1 (en) | 2023-07-31 | 2025-02-06 | T-Knife Gmbh | An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease |
| WO2025045752A1 (en) | 2023-08-25 | 2025-03-06 | T-Knife Gmbh | Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025146286A1 (en) | 2024-01-04 | 2025-07-10 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025190565A1 (en) | 2024-03-13 | 2025-09-18 | T-Knife Gmbh | A chimeric programmed cell death protein 1 receptor |
| WO2025191067A1 (en) | 2024-03-13 | 2025-09-18 | T-Knife Gmbh | A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1812095A (en) | 1994-02-23 | 1995-09-11 | Akzo Nobel N.V. | A t cell receptor sequence specifically associated with an immune disease |
| US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
-
2014
- 2014-01-29 EP EP20167194.8A patent/EP3747899A3/en active Pending
- 2014-01-29 SI SI201431600T patent/SI2951202T1/sl unknown
- 2014-01-29 AU AU2014211454A patent/AU2014211454B2/en active Active
- 2014-01-29 JP JP2015554209A patent/JP6639233B2/ja active Active
- 2014-01-29 CA CA2899679A patent/CA2899679C/en active Active
- 2014-01-29 DK DK14702238.8T patent/DK2951202T3/da active
- 2014-01-29 WO PCT/EP2014/051726 patent/WO2014118236A2/en not_active Ceased
- 2014-01-29 EP EP14702238.8A patent/EP2951202B1/en active Active
- 2014-01-29 PL PL14702238T patent/PL2951202T3/pl unknown
- 2014-01-29 ES ES14702238T patent/ES2804538T3/es active Active
- 2014-01-29 CN CN201480016900.3A patent/CN105377886B/zh active Active
- 2014-01-29 US US14/763,421 patent/US10377808B2/en active Active
- 2014-01-29 PT PT147022388T patent/PT2951202T/pt unknown
- 2014-01-29 HU HUE14702238A patent/HUE050390T2/hu unknown
-
2018
- 2018-07-05 AU AU2018204891A patent/AU2018204891B2/en active Active
-
2019
- 2019-07-10 US US16/507,803 patent/US11447536B2/en active Active
-
2022
- 2022-09-17 US US17/933,088 patent/US12338272B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018204891A1 (en) | 2018-07-26 |
| EP2951202A2 (en) | 2015-12-09 |
| US20150353622A1 (en) | 2015-12-10 |
| DK2951202T3 (da) | 2020-07-13 |
| JP6639233B2 (ja) | 2020-02-05 |
| US20190375816A1 (en) | 2019-12-12 |
| US12338272B2 (en) | 2025-06-24 |
| SI2951202T1 (sl) | 2020-08-31 |
| JP2016505635A (ja) | 2016-02-25 |
| AU2014211454A1 (en) | 2015-09-17 |
| US10377808B2 (en) | 2019-08-13 |
| AU2018204891B2 (en) | 2020-03-12 |
| CN105377886A (zh) | 2016-03-02 |
| WO2014118236A8 (en) | 2014-12-18 |
| WO2014118236A3 (en) | 2014-10-09 |
| EP3747899A2 (en) | 2020-12-09 |
| PT2951202T (pt) | 2020-07-07 |
| WO2014118236A2 (en) | 2014-08-07 |
| HUE050390T2 (hu) | 2020-11-30 |
| EP2951202B1 (en) | 2020-04-08 |
| US20230025572A1 (en) | 2023-01-26 |
| AU2014211454B2 (en) | 2018-04-05 |
| CA2899679C (en) | 2023-03-21 |
| EP3747899A3 (en) | 2021-02-24 |
| CA2899679A1 (en) | 2014-08-07 |
| ES2804538T3 (es) | 2021-02-08 |
| CN105377886B (zh) | 2020-07-28 |
| HK1218551A1 (en) | 2017-02-24 |
| US11447536B2 (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2951202T (pt) | Moléculas de ligação de alta avidez que reconhecem mage-a1 | |
| IL240838A0 (en) | Anti-3–lag binding proteins | |
| GB201311487D0 (en) | Bispecific molecules | |
| GB201317928D0 (en) | Molecule | |
| GB201305545D0 (en) | Compression device | |
| GB201320571D0 (en) | Glycan analysis | |
| SG11201604663SA (en) | Cd44 binding peptides | |
| GB201310639D0 (en) | Supercharger assembly | |
| ME03767B (me) | Pneumatski odstranjivač listova | |
| ZA201507808B (en) | Binding element | |
| GB201302878D0 (en) | Modified igG molecules | |
| GB201308738D0 (en) | Novel polymer conjugates | |
| GB201319558D0 (en) | Functionalized proppants | |
| GB201404622D0 (en) | Compression element | |
| TWM475530U (en) | Leaf chain | |
| GB201317061D0 (en) | Compression device | |
| GB201314294D0 (en) | Binding surfaces | |
| GB201312200D0 (en) | Heparin binding peptides | |
| IL229812A (en) | Bookmark | |
| PH22013000538U1 (en) | Bookmark | |
| GB201305465D0 (en) | Novel peptides | |
| GB201306192D0 (en) | Novel methods | |
| AU2013903236A0 (en) | Hydrocarbon extraction | |
| GB201307718D0 (en) | Compression device | |
| GB201305081D0 (en) | Compression device |